Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Fuji
Teva
Cerilliant
Moodys
Daiichi Sankyo
US Department of Justice
Mallinckrodt
Federal Trade Commission

Generated: June 20, 2018

DrugPatentWatch Database Preview

Horizon Pharma Usa Company Profile

« Back to Dashboard

Summary for Horizon Pharma Usa
International Patents:153
US Patents:22
Tradenames:2
Ingredients:2
NDAs:2
Patent Litigation for Horizon Pharma Usa: See patent lawsuits for Horizon Pharma Usa

Drugs and US Patents for Horizon Pharma Usa

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-001 Apr 30, 2010 AB RX Yes Yes 9,198,888 ➤ Try a Free Trial ➤ Try a Free Trial
Horizon Pharma Usa PROCYSBI cysteamine bitartrate CAPSULE, DELAYED RELEASE;ORAL 203389-001 Apr 30, 2013 RX Yes No 9,198,882*PED ➤ Try a Free Trial Y ➤ Try a Free Trial
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-001 Apr 30, 2010 AB RX Yes Yes 7,411,070*PED ➤ Try a Free Trial Y ➤ Try a Free Trial
Horizon Pharma Usa PROCYSBI cysteamine bitartrate CAPSULE, DELAYED RELEASE;ORAL 203389-001 Apr 30, 2013 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Horizon Pharma Usa

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-001 Apr 30, 2010 6,875,872*PED ➤ Try a Free Trial
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-002 Apr 30, 2010 5,714,504*PED ➤ Try a Free Trial
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-002 Apr 30, 2010 6,875,872*PED ➤ Try a Free Trial
Horizon Pharma Usa VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-001 Apr 30, 2010 5,900,424*PED ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for HORIZON PHARMA USA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablet 375 mg/20 mg and 500 mg/20 mg ➤ Subscribe 2010-11-05

Non-Orange Book US Patents for Horizon Pharma Usa

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,466,175 Form of S-omeprazole ➤ Try a Free Trial
9,814,689 Enterically coated cysteamine, cystamine and derivatives thereof ➤ Try a Free Trial
8,865,190 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Try a Free Trial
9,364,439 Pharmaceutical compositions for the coordinated delivery of NSAIDs ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Horizon Pharma Usa Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00481 Netherlands ➤ Try a Free Trial PRODUCT NAME: NAPROXEN EN ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17901/0263-001 20101105
11/016 Ireland ➤ Try a Free Trial PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
2011005 Lithuania ➤ Try a Free Trial PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
0649 Netherlands ➤ Try a Free Trial PRODUCT NAME: CYSTEAMINE; REGISTRATION NO/DATE: EU/1/13/861/001-002 20130910
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
QuintilesIMS
Julphar
Express Scripts
US Army
Boehringer Ingelheim
US Department of Justice
Covington
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.